Cereblon通过降解Cav1.2α促进心脏功能障碍
该研究探讨了Cereblon(CRBN)在射血分数降低的心力衰竭(HFrEF)中的作用。HFrEF患者心脏组织中CRBN水平升高;全身或心脏特异性敲除CRBN的小鼠心肌收缩力增强、L型钙通道电流(ICaL)增加,机制上CRBN的Lon结构域直接结合Cav1.2α的N端,促进其泛素化蛋白酶体降解;使用PROTAC类CRBN降解剂TD-165可增加Cav1.2α表面表达和ICaL,低CRBN水平在体内保护心脏免受心肌病。结论:CRBN选择性降解Cav1.2α并促进心脏功能障碍,降低CRBN水平可能是HFrEF的治疗策略。
要点
- HFrEF患者心脏组织中CRBN水平升高。
- CRBN直接结合Cav1.2α并促进其泛素化降解,降低ICaL。
- 敲除或药物降解CRBN可增加Cav1.2α表达和ICaL,保护心脏功能。
核心结论
- Cereblon选择性降解Cav1.2α,进而促进心脏功能障碍。
- 降低CRBN水平的靶向方法可能成为HFrEF的治疗策略。
研究设计与样本
- 研究纳入HFrEF患者心脏组织与对照比较CRBN水平。
- 使用全身CRBN敲除(CRBN-/-)和心脏特异性敲除(Crbnfl/fl/Myh6Cre+)小鼠进行体内外研究。
- 使用新型PROTAC类CRBN降解剂TD-165进行药理学耗竭实验。
主要发现
- HFrEF患者心脏组织中CRBN水平较对照升高。
- 全身和心脏特异性CRBN敲除小鼠心肌收缩力增强,LTCC电流(ICaL)增加。
- CRBN的Lon结构域直接结合Cav1.2α的N端。
- 增加CRBN水平增强Cav1.2α的泛素化和蛋白酶体降解,降低ICaL。
- 遗传或药理学(TD-165)耗竭CRBN增加Cav1.2α表面表达和ICaL,低CRBN水平在体内保护心脏免受心肌病。
临床怎么用
- CRBN可能作为HFrEF的潜在治疗靶点。
- PROTAC类CRBN降解剂TD-165在实验中显示增加Cav1.2α表达和ICaL的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Cereblon (CRBN) is a substrate receptor of the E3 ubiquitin ligase complex that was reported to target ion channel proteins. L-type voltage-dependent Ca2+ channel (LTCC) density and dysfunction is a critical player in heart failure with reduced ejection fraction (HFrEF). However, the underlying cellular mechanisms by which CRBN regulates LTCC subtype Cav1.2α during cardiac dysfunction remain unclear. Here, we explored the role of CRBN in HFrEF by investigating the direct regulatory role of CRBN in Cav1.2α activity and examining how it can serve as a target to address myocardial dysfunction. METHODS AND RESULTS: Cardiac tissues from HFrEF patients exhibited increased levels of CRBN compared with controls. In vivo and ex vivo studies demonstrated that whole-body CRBN knockout (CRBN-/-) and cardiac-specific knockout mice (Crbnfl/fl/Myh6Cre+) exhibited enhanced cardiac contractility with increased LTCC current (ICaL) compared with their respective controls, which was modulated by the direct interaction of CRBN with Cav1.2α. Mechanistically, the Lon domain of CRBN directly interacted with the N-terminal of Cav1.2α. Increasing CRBN levels enhanced the ubiquitination and proteasomal degradation of Cav1.2α and decreased ICaL. In contrast, genetic or pharmacological depletion of CRBN via TD-165, a novel PROTAC-based CRBN degrader, increased surface expression of Cav1.2α and enhanced ICaL. Low CRBN levels protected the heart against cardiomyopathy in vivo. CONCLUSION: Cereblon selectively degrades Cav1.2α, which in turn facilitates cardiac dysfunction. A targeted approach or an efficient method of reducing CRBN levels could serve as a promising strategy for HFrEF therapeutics.
引用
- Park N, Marquez J, Pham TK, et al. Cereblon contributes to cardiac dysfunction by degrading Cav1.2α. Eur Heart J. 2022. PMID: 35190817. doi:10.1093/eurheartj/ehac072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。